Clark has more than 15 years of commercial and managerial experience in the biotech and pharma industry. His strengths are in business and corporate development, licensing, M&A and in particular deal execution, having executed over 20 major transactions. Dr Clark was formerly Chief Business Officer at Syntaxin, (successfully divested to Ipsen Pharma), Vice-President of business development at Vernalis and a member of the senior executive committee as well as President, Vernalis Canada. He has also held leadership roles at Ribotargets and British Biotech and was co-head of the Biotech business unit at Datamonitor.  Clark has more than 15 years of commercial and managerial experience in the biotech and pharma industry. His strengths are in business and corporate development, licensing, M&A and in particular deal execution, having executed over 20 major transactions. Dr Clark was formerly Chief Business Officer at Syntaxin, (successfully divested to Ipsen Pharma), Vice-President of business development at Vernalis and a member of the senior executive committee as well as President, Vernalis Canada. He has also held leadership roles at Ribotargets and British Biotech and was co-head of the Biotech business unit at Datamonitor.

fermentation